RA CAPITAL MANAGEMENT, L.P. — 13F Holdings & Portfolio
CIK 1346824 · latest 13F-HR filed 2026-08-14
RA CAPITAL MANAGEMENT, L.P. manages $11.51B in 13F-reported U.S. long-equity assets across 85 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ASND (23.83%), PBLS (6.88%), RYTM (6.43%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions and exited 18; 38 existing positions rose in reported value and 13 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Loading holdings…
AUM
$11.51B
Long-equity book
Holdings
85
Distinct positions
Period
2026-06-30
Filed 2026-08-14
Q/Q Activity
+17 / −18 / ↑38 / ↓13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26ASND23.8% · 0%PBLS6.9% · newRYTM6.4% · 0%PCVX5.8% · 0%SION3.8% · 0%TYRA3.4% · 0%EWTX3.0% · -20%NAMS2.8% · 0%COAG2.5% · newSEPN2.0% · 0%BCAX1.9% · 0%MLYS1.8% · 0%GHRS1.8% · -0%IRON1.6% · 0%SGP1.6% · 0%ARTV1.5% · +82%JANX1.5% · 0%TSHA1.4% · 0%BCRX1.4% · 0%WVE1.4% · 0%NUVL1.3% · -51%ABVX1.3% · newORKA1.3% · newCLYM1.3% · 0%SLDB1.0% · +29%ZLAB0.9% · +1%SPRY0.8% · 0%XNCR0.7% · +8%JBIO0.7% · 0%NTLA0.7% · newLBRX0.6% · 0%DFTX0.6% · newACRS0.6% · +87%FDMT0.6% · 0%SANA0.6% · newDMRA0.5% · 0%MNPR0.5% · 0%ABOS0.5% · 0%GERN0.5% · -33%RZLT0.4% · +3%EVMN0.4% · 0%VOR0.4% · -56%IPSC0.4% · 0%AKTS0.4% · -13%BIOA0.4% · +1%CCCC0.3% · 0%MIRM0.3% · 0%CAPR0.3% · 0%PEPG0.3% · 0%PRLD0.3% · newNKTX0.3% · 0%QTTB0.3% · newAVR0.3% · 0%EDIT0.2% · newOVID0.2% · -2%ASMB0.2% · 0%ALXO0.2% · 0%BNTC0.2% · 0%LENZ0.2% · 0%LXEO0.2% · 0%
Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 60.4%Cumulative share of the portfolio held in the largest N positions.
Firm Profile & Key People
As of the firm’s regulatory filing dated Mar 31, 2026.
Assets Under Management
$16.40B
Discretionary
$16.40B
Employees
185
Accounts
13
Address
200 BERKELEY STREET
18TH FLOOR
BOSTON, MA 02116
18TH FLOOR
BOSTON, MA 02116
Phone
(617) 778-2500
This firm reports 3 disclosure items on its registration.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| KOLCHINSKY, PETER, (NMN) Control | PORTFOLIO MANAGER since Oct 2019 | Less than 5% | Individual |
| PETER KOLCHINSKY REVOCABLE TRUST Control | PARTNER since Oct 2019 | 50–75% | Domestic Entity |
| RAJEEV M. SHAH FAMILY REVOCABLE TRUST Control | PARTNER since Oct 2019 | 10–25% | Domestic Entity |
| RANDALL, CRAIG, ALAN Control | GENERAL COUNSEL since Jan 2026 | Less than 5% | Individual |
| ROSE, ERIC, PAUL Control | CHIEF COMPLIANCE OFFICER since Oct 2019 | Less than 5% | Individual |
| SANDERS, ROBERT, BRENT Control | CHIEF INFORMATION OFFICER since Jul 2025 | Less than 5% | Individual |
| SAULNIER, MICHAEL Control | CHIEF FINANCIAL OFFICER since Jan 2021 | Less than 5% | Individual |
| SHAH, RAJEEV, MAHESH Control | PORTFOLIO MANAGER since Oct 2019 | Less than 5% | Individual |
| ALDRICH, RICHARD, H. (MI ONLY) | PARTNER since Oct 2019 | 10–25% | Individual |
| KOLCHINSKY, PETER, (NMN) Control Indirect owner via PETER KOLCHINSKY REVOCABLE TRUST | TRUSTEE since Oct 2019 | General partner, trustee or manager | Individual |
| SHAH, RAJEEV, MAHESH Control Indirect owner via RAJEEV M. SHAH FAMILY REVOCABLE TRUST | TRUSTEE since Oct 2019 | General partner, trustee or manager | Individual |
Ownership & leadership changes · 13 filings with changes since Feb 14, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
Mar 31, 2026 filing
- No longer listedCALIRI, CHRISTOPHER, JAMES · CHIEF INFORMATION OFFICER · Less than 5% · control person · listed since Dec 2018
- No longer listedGORGONE, CHRISTOPHER, LEE · HEAD OF CAPITAL FORMATION AND INVESTOR RELATIONS · Less than 5% · control person · listed since Jul 2024
- No longer listedREED, SARAH, WATT BURGESS · GENERAL COUNSEL · Less than 5% · control person · listed since Oct 2019
- AddedRANDALL, CRAIG, ALAN · GENERAL COUNSEL · Less than 5% · control person
- AddedSANDERS, ROBERT, BRENT · CHIEF INFORMATION OFFICER · Less than 5% · control person
Mar 31, 2025 filing
- AddedGORGONE, CHRISTOPHER, LEE · HEAD OF CAPITAL FORMATION AND INVESTOR RELATIONS · Less than 5% · control person
Mar 29, 2024 filing
- No longer listedBOELHOUWER, PIETER, JAMES ALEXANDER · MANAGING DIRECTOR OF STRATEGY AND OPERATIONS · Less than 5% · control person · listed since Dec 2017
Mar 31, 2021 filing
- No longer listedDANIELS, AMANDA, LYNN · CHIEF OPERATING OFFICER · Less than 5% · control person · listed since Feb 2012
- No longer listedWU, KAI, CHEONG · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since May 2016
- AddedSAULNIER, MICHAEL · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Nov 1, 2019 filing
- No longer listedKASSIAN, NATASHA, MARIA · GENERAL COUNSEL, CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Mar 2018
- AddedKOLCHINSKY, PETER, (NMN) · TRUSTEE · General partner, trustee or manager · indirect via PETER KOLCHINSKY REVOCABLE TRUST · control person
- AddedPETER KOLCHINSKY REVOCABLE TRUST · PARTNER · 50–75% · control person
- AddedRAJEEV M. SHAH FAMILY REVOCABLE TRUST · PARTNER · 10–25% · control person
- AddedREED, SARAH, WATT BURGESS · GENERAL COUNSEL · Less than 5% · control person
- AddedROSE, ERIC, PAUL · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- AddedSHAH, RAJEEV, MAHESH · TRUSTEE · General partner, trustee or manager · indirect via RAJEEV M. SHAH FAMILY REVOCABLE TRUST · control person
- ChangedALDRICH, RICHARD, H. (MI ONLY) · title CLASS C MEMBER → PARTNER
- ChangedKOLCHINSKY, PETER, (NMN) · title MANAGING MEMBER, PORTFOLIO MANAGER → PORTFOLIO MANAGER; ownership 50–75% → Less than 5%
- ChangedSHAH, RAJEEV, MAHESH · title CLASS B MEMBER, PORTFOLIO MANAGER → PORTFOLIO MANAGER; ownership 10–25% → Less than 5%
Mar 29, 2019 filing
- AddedCALIRI, CHRISTOPHER, JAMES · CHIEF INFORMATION OFFICER · Less than 5% · control person
Mar 30, 2018 filing
- No longer listedMCGRATH, NICHOLAS, MYLES · GENERAL COUNSEL, CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since May 2016
- AddedKASSIAN, NATASHA, MARIA · GENERAL COUNSEL, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Jan 2, 2018 filing
- AddedBOELHOUWER, PIETER, JAMES ALEXANDER · MANAGING DIRECTOR OF STRATEGY AND OPERATIONS · Less than 5% · control person
May 12, 2016 filing
- No longer listedMEISNER, DEREK, MICHAEL · GENERAL COUNSEL, CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Jan 2015
- AddedMCGRATH, NICHOLAS, MYLES · GENERAL COUNSEL, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- AddedWU, KAI, CHEONG · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Apr 21, 2016 filing
- No longer listedWOLF, CHRISTOPHER, JAMES · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jun 2015
Older changes (4 more filings)
Jun 9, 2015 filing
- AddedWOLF, CHRISTOPHER, JAMES · CHIEF FINANCIAL OFFICER · Less than 5% · control person
Jan 16, 2015 filing
- AddedMEISNER, DEREK, MICHAEL · GENERAL COUNSEL, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedDANIELS, AMANDA, LYNN · title DIRECTOR OF OPERATIONS AND CHIEF COMPLIANCE OFFICER → CHIEF OPERATING OFFICER; now a control person
- ChangedSHAH, RAJEEV, MAHESH · now a control person
Mar 31, 2014 filing
- AddedSHAH, RAJEEV, MAHESH · CLASS B MEMBER, PORTFOLIO MANAGER · 10–25%
- ChangedDANIELS, AMANDA, LYNN · title OPERATIONS MANAGER AND CHIEF COMPLIANCE OFFICER → DIRECTOR OF OPERATIONS AND CHIEF COMPLIANCE OFFICER
Feb 14, 2012 filing (earliest on record)
- ListedALDRICH, RICHARD, H. (MI ONLY) · CLASS C MEMBER · 10–25%
- ListedDANIELS, AMANDA, LYNN · OPERATIONS MANAGER AND CHIEF COMPLIANCE OFFICER · Less than 5%
- ListedKOLCHINSKY, PETER, (NMN) · MANAGING MEMBER, PORTFOLIO MANAGER · 50–75% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- RHYTHM PHARMACEUTICALS INC$160.4M +27.7%
- ARTIVA BIOTHERAPEUTICS INC$110.7M +174.5%
- GH RESEARCH PLC$97.3M +90.2%
- BICARA THERAPEUTICS INC$71.1M +49.3%
- CLIMB BIO INC$70.0M +90.4%
Top Trims
- NUVALENT INC-A-$105.7M -40.7%
- TYRA BIOSCIENCES INC-$77.6M -16.6%
- VOR BIOPHARMA INC-$52.2M -54.1%
- GERON CORP-$40.2M -42.3%
- WAVE LIFE SCIENCES LTD-$38.8M -19.9%
New Positions
- ASCENDIS PHARMA A/S$2.74B
- PARABILIS MEDICINES INC$791.9M
- HEMAB THERAPEUTICS HOLDINGS$286.8M
- ABIVAX SA-ADR$150.9M
- ORUKA THERAPEUTICS INC$148.0M
Exited Positions
- ASCENDIS PHARMA A/S - ADR$2.35B
- DIANTHUS THERAPEUTICS INC$219.2M
- PRAXIS PRECISION MEDICINES I$120.4M
- SAREPTA THERAPEUTICS INC$84.9M
- SPYRE THERAPEUTICS INC$81.8M
RA CAPITAL MANAGEMENT, L.P. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ASCENDIS PHARMA A/S | ASND | K08588103 | $2.74B | 23.83% | 10,281,496 | SH |
| 2 | PARABILIS MEDICINES INC | PBLS | 698955101 | $791.9M | 6.88% | 28,933,371 | SH |
| 3 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $740.2M | 6.43% | 6,666,837 | SH |
| 4 | VAXCYTE INC | PCVX | 92243G108 | $667.0M | 5.80% | 11,474,599 | SH |
| 5 | SIONNA THERAPEUTICS INC | SION | 829401108 | $435.7M | 3.79% | 9,905,045 | SH |
| 6 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $389.6M | 3.39% | 12,198,625 | SH |
| 7 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $341.0M | 2.96% | 8,392,730 | SH |
| 8 | NEWAMSTERDAM PHARMA CO NV | NAMS | N62509109 | $323.7M | 2.81% | 9,550,191 | SH |
| 9 | HEMAB THERAPEUTICS HOLDINGS | COAG | 423494103 | $286.8M | 2.49% | 7,808,627 | SH |
| 10 | SEPTERNA INC | SEPN | 81734D104 | $234.3M | 2.04% | 6,995,858 | SH |
| 11 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $215.4M | 1.87% | 7,255,993 | SH |
| 12 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $207.6M | 1.80% | 7,692,750 | SH |
| 13 | GH RESEARCH PLC | GHRS | G3855L106 | $205.3M | 1.78% | 7,636,813 | SH |
| 14 | DISC MEDICINE INC | IRON | 254604101 | $179.2M | 1.56% | 2,450,221 | SH |
| 15 | SPYGLASS PHARMA INC | SGP | 85220G109 | $178.6M | 1.55% | 8,021,117 | SH |
| 16 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $174.2M | 1.51% | 17,955,642 | SH |
| 17 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $171.9M | 1.49% | 11,189,693 | SH |
| 18 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $160.4M | 1.39% | 23,555,648 | SH |
| 19 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $158.3M | 1.38% | 15,827,186 | SH |
| 20 | WAVE LIFE SCIENCES LTD | WVE | Y95308105 | $156.7M | 1.36% | 26,975,505 | SH |
| 21 | NUVALENT INC-A | NUVL | 670703107 | $153.9M | 1.34% | 1,246,456 | SH |
| 22 | ABIVAX SA-ADR | ABVX | 00370M103 | $150.9M | 1.31% | 1,132,557 | SH |
| 23 | ORUKA THERAPEUTICS INC | ORKA | 687604108 | $148.0M | 1.29% | 1,554,597 | SH |
| 24 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $120.2M | 1.04% | 12,036,126 | SH |
| 25 | CLIMB BIO INC | CLYM | 28658R106 | $115.0M | 1.00% | 8,821,067 | SH |
| 26 | ZAI LAB LTD-ADR | ZLAB | 98887Q104 | $109.1M | 0.95% | 5,743,533 | SH |
| 27 | ARS PHARMACEUTICALS INC | SPRY | 82835W108 | $87.0M | 0.76% | 10,860,977 | SH |
| 28 | XENCOR INC | XNCR | 98401F105 | $84.9M | 0.74% | 5,274,274 | SH |
| 29 | JADE BIOSCIENCES INC | JBIO | 008064206 | $81.6M | 0.71% | 3,671,083 | SH |
| 30 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $76.6M | 0.67% | 4,526,926 | SH |
| 31 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $71.7M | 0.62% | 2,208,604 | SH |
| 32 | DEFINIUM THERAPEUTICS INC | DFTX | 24477V105 | $70.6M | 0.61% | 1,500,000 | SH |
| 33 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $67.3M | 0.58% | 12,723,026 | SH |
| 34 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $67.2M | 0.58% | 5,049,779 | SH |
| 35 | SANA BIOTECHNOLOGY INC | SANA | 799566104 | $65.4M | 0.57% | 18,750,000 | SH |
| 36 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $62.4M | 0.54% | 2,399,702 | SH |
| 37 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $61.8M | 0.54% | 667,207 | SH |
| 38 | ACUMEN PHARMACEUTICALS INC | ABOS | 00509G209 | $56.1M | 0.49% | 20,992,669 | SH |
| 39 | GERON CORP | GERN | 374163103 | $54.8M | 0.48% | 42,809,751 | SH |
| 40 | REZOLUTE INC | RZLT | 76200L309 | $49.1M | 0.43% | 9,445,039 | SH |
| 41 | EVOMMUNE INC | EVMN | 30054Y107 | $46.4M | 0.40% | 3,494,638 | SH |
| 42 | VOR BIOPHARMA INC | VOR | 929033207 | $44.2M | 0.38% | 2,402,095 | SH |
| 43 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $43.5M | 0.38% | 17,754,430 | SH |
| 44 | AKTIS ONCOLOGY INC | AKTS | 01021M104 | $42.4M | 0.37% | 1,314,405 | SH |
| 45 | BIOAGE LABS INC | BIOA | 09077V100 | $41.0M | 0.36% | 1,671,648 | SH |
| 46 | C4 THERAPEUTICS INC | CCCC | 12529R107 | $37.4M | 0.32% | 8,000,000 | SH |
| 47 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $37.3M | 0.32% | 318,554 | SH |
| 48 | CAPRICOR THERAPEUTICS INC | CAPR | 14070B309 | $36.3M | 0.32% | 1,507,844 | SH |
| 49 | PEPGEN INC | PEPG | 713317105 | $36.1M | 0.31% | 20,064,545 | SH |
| 50 | PRELUDE THERAPEUTICS INC | PRLD | 74065P101 | $34.5M | 0.30% | 6,475,882 | SH |
Filing History
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $11.51B | 85 | 0001104659-26-097251 |
| 2026-03-31 | 2026-05-15 | $9.44B | 86 | 0001104659-26-062637 |
| 2025-12-31 | 2026-02-17 | $9.76B | 72 | 0001104659-26-016482 |
| 2025-09-30 | 2025-11-14 | $8.12B | 68 | 0001104659-25-112469 |
Filer Information
Address
200 BERKELEY STREET, 18TH FLOORBOSTON, MA 02116
Phone
(617) 778-2500
Filing Manager
RA CAPITAL MANAGEMENT, L.P.
BOSTON, MA
Signatory
Rajeev Shah
Authorized Signatory